Institutional investors and hedge funds own 23.65% of the company's stock. (NASDAQ:OPK) during the first quarter, according to its most recent 13F filing with the SEC.
In other news, Vice Chairman Jane Ph D. Hsiao bought 40,000 shares of the stock in a transaction on Wednesday, May 10th.
Shares of Opko are now trading at $6.84, down $0.24 or -3.32%.
On Thursday, June 15th, Phillip Md Et Al Frost acquired 200,000 shares of Opko Health stock. Piedmont Investment Advisors LLC now holds 160,825 shares with a value of $1,287,000. As a stock trades within its 52-week price range (the range that exists between the 52-week low and the 52-week high), shareholders may show raised interest as price nears either the high or the low. The total value of its holdings decreased 6.7%. 1,562,122 shares of the company's stock were exchanged. The stock was purchased at an average price of $6.11 per share, for a total transaction of $1,269,047.00. The stock was bought at an average cost of $6.31 per share, with a total value of $407,626.00. Opko Health has a 12 month low of $5.99 and a 12 month high of $12.15. (NASDAQ:OPK) in a research report report published on Friday, June 16th. The company's average Piotroski F-Score: 3 during the last 7 years. Opko Health Inc. (NASDAQ:OPK) has declined 32.62% since June 22, 2016 and is downtrending. The net profit margin for the company is reported at 1.60% while the weekly performance for the same has been recorded at -3.40%.
Opko Health Inc (NASDAQ:OPK)'s revenue estimates for the current quarter are $322.64 Million according to 5 number of analysts, for the current quarter the company has high revenue estimates of $336.1 Million in contradiction of low revenue estimates of $313.1 Million. During the same period previous year, the firm posted ($0.02) earnings per share. The firm's quarterly revenue was up 1.8% on a year-over-year basis. Equities research analysts expect that Opko Health, Inc. will post ($0.20) earnings per share for the current fiscal year. The FCF Growth of Opko Health, Inc. "(OPK) CEO Phillip Md Et Al Frost Buys 207,700 Shares" was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of United States & worldwide trademark and copyright law.More news: Portugal, Mexico, Russia tussle for semi-final berths
Karp Capital Management Corp bought a new stake in shares of Opko Health, Inc.
Several research analysts have recently weighed in on the stock. Jefferies Group LLC decreased their price target on shares of Opko Health from $10.00 to $8.00 and set a hold rating on the stock in a report on Thursday, March 2nd. Zacks Investment Research downgraded shares of Opko Health from a "hold" rating to a "sell" rating in a research note on Friday, March 3rd. Standpoint Research reiterated a "buy" rating and issued a $14.00 price objective on shares of Opko Health in a research report on Sunday, March 5th. Opko Health, Inc.'s average EBITDA per Share Growth Rate was 240 percent during the past 12 months.
JP Morgan began coverage of the stock giving it an initial rating of "Overweight" and projecting a price target of $14.00. World Asset Management Inc increased its stake in Opko Health by 23.6% in the first quarter. National Planning Corp now owns 16,240 shares of the biotechnology company's stock valued at $138,000 after buying an additional 200 shares in the last quarter. AQR Capital Management LLC acquired a new position in Opko Health during the fourth quarter valued at $105,000. The third largest holder is State Street Corp, which now holds $77.36 million worth of this stock and that ownership represents almost 2.09% of its market capitalization.
Clal Insurance Enterprises Holdings Ltd increased Perrigo Co Plc Shs (PRGO) stake by 103.01% reported in 2016Q4 SEC filing. RK Asset Management LLC now owns 887,719 shares of the biotechnology company's stock valued at $7,102,000 after buying an additional 3,300 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Opko Health during the fourth quarter valued at about $648,000. Baird Financial Group Inc. now owns 52,871 shares of the biotechnology company's stock worth $492,000 after buying an additional 2,558 shares in the last quarter.
"The updated KDIGO guideline highlights the unmet needs that exist in the treatment of SHPT, and we are working with physicians and other health care professionals to address these needs with Rayaldee", said Charles W. Bishop, PhD, CEO of the OPKO Health Renal Division. The pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations.